Cytochrome P450 activity in rheumatoid arthritis patients during continuous IL-6 receptor antagonist therapy.
Ann-Cathrine Dalgård DunvaldKasper SøltoftEkta SheetalSøren Andreas JustIda Emilie Brejning FrederiksenFlemming NielsenDorte Aalund OlsenJonna Skov MadsenOliver HendricksTore Bjerregaard StagePublished in: European journal of clinical pharmacology (2023)
Based on sparse data from three patients, continuous anti-IL-6R therapy seems to cause an acute but transient increase in CYP3A4 activity in rheumatoid arthritis patients, which may be due to a normalization of the inflammation-suppressed CYP activity. Further studies are warranted to understand the mechanism behind this putative transient effect. Trial registration Registered in the ClinicalTrials.gov database (identifier NCT04842981) on April 13th, 2021.
Keyphrases
- rheumatoid arthritis patients
- disease activity
- end stage renal disease
- ejection fraction
- newly diagnosed
- oxidative stress
- chronic kidney disease
- rheumatoid arthritis
- clinical trial
- systemic lupus erythematosus
- prognostic factors
- study protocol
- emergency department
- bone marrow
- deep learning
- open label
- data analysis
- replacement therapy
- case control